ALBI Grade for Hepatocellular Carcinoma
Albumin-Bilirubin (ALBI) grade is a simple objective model for assessing liver function in patients with HCC. An alternative to Child-Pugh without subjective components.
Score interpretation
ALBI Grade 1 (score ≤−2.60) — well-preserved liver function
→ Suitable for aggressive treatment (surgery, ablation, TACE); full HCC treatment options available
ALBI Grade 2 (score −2.60 to −1.39) — moderate hepatic dysfunction
→ Careful patient selection for treatment; consider toxicity risk; TACE/ablation may still be appropriate
ALBI Grade 3 (score >−1.39) — severe hepatic dysfunction
→ Palliative or best supportive care; liver transplant evaluation; systemic therapy poorly tolerated
Interpretation bands for the ALBI Grade. Apply clinical judgement and local guidance.
References
- Johnson PJ et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach — the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Albumin solution · Plasma derivative / colloid
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.